Drug-Free Migraine Treatment CEFALY®: Publication of a Study Conducted on 2,313 Patients

The scientific journal "JOURNAL of HEADACHE and PAIN" publishes positive results from a clinical study conducted on 2,313 patients which confirms the high efficacy and safety of the medical device CEFALY ® migraine treatment


LIEGE, Belgium, Jan. 8, 2014 /CNW/ - The efficacy and safety of the CEFALY ® medical device for migraine treatment had already been reported early 2013 in the scientific journal "Neurology" (Official Journal of the American Academy of Neurology). Today published data on a large number of individuals confirm the significant improvement for a majority of patients. Following 2 months of treatment, 54.4% of the patients described a very substantial improvement and decided to purchase the device. If we rule out those patients who didn't use the device or who only used it to a negligible degree, and take into account only regular users, the percentage of patients with a very significant improvement reaches 81%. Side effects are reported by only 4.3% of patients, all of which are minor and completely reversible. Therefore the effectiveness/safety ratio is excellent.

Current anti-migraine medications are only moderately effective and often not well tolerated. In addition, overuse of anti-migraine medications is an essential factor in the worsening of the disease and its development into chronic migraine. Cefaly ® is therefore a means of choice to treat a majority of migraine patients.

Cefaly® is an innovative medical device protected by a number of patents. It is the first device to offer external cranial neurostimulation. Cranial neurostimulation is a technique that has been used for a number of years in neurology, but this has been carried out using implantable neurostimulators (similar to pacemakers). The technological advances made by Cefaly means that there is now a simple, lightweight, economical and comfortable device available that offers migraine patients a method of treatment that is neither drug-based nor invasive.

A self-adhesive electrode is placed on the forehead and the device is positioned on this electrode, worn like a pair of glasses. Highly precise impulses are transmitted through the electrode to the nerve endings of the upper branch of the trigeminal nerve.

The Cefaly® medical device is available on the European market and in Canada; FDA approval for USA is expected in the coming months.



For further information: CEFALY Technology : ZI des Hauts Sarts, 4ème Avenue N°5, B-4040, Herstal, Liège, Belgium. Phone: +3243676722; Fax: +3243676702; info@cefaly.com. Press Contact: Aurélie SERVAES, Mobile: +32473487166, a.servaes@cefaly.com

Organization Profile

CEFALY Technology

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890